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INTRODUCTION
Ovarian cancer remains the third most
frequent gynecological neoplasm and corresponds
to the highest mortality rate in developed
countries.1 In Brazil, according to Datasus files,
the incidence of malignant ovarian tumors was
reported to be 3.6 per 100,000 women in 1998,
resulting in 1830 deaths in the same year.2 A worse
prognosis is correlated with late diagnosis. Up to
70% of the cases are detected at advanced stages,
with increased ovarian disease, in which the
mortality rate reaches 70% within two years and
90% within five years, which has encouraged
research into ovarian cancer screening methods.1,3,4
However, these are costly methods and, because
of their elevated false-positive results, they have
been ineffective.5 Ovarian tumors are presented
as adnexal masses which give rise to a number of
different benign and malignant conditions. The
accurate diagnosis of an adnexal mass is a challenge
for the gynecologist, because of its bizarre and
atypical behaviour.6,7 Preoperative diagnostic
procedures that are able to distinguish whether
an ovarian neoplasm is malignant or benign, could
be useful in planning optimized treatment. Until
now, the standard strategy for differential diagnosis
has been exploratory laparotomy. On the other
hand, detailed analysis of the origin of the pelvic
mass has encouraged the use of minimal invasive
surgery, such as laparoscopy or mini-laparotomy,
in selected cases.8-10 A preoperative suggestion of
malignancy can guide the gynecologist to refer
women with suspected pelvic masses to an
oncological unit for appropriate therapy and
optimized debulking.6,7,11
Several diagnostic methods for pelvic masses
have been reported, such as abdominal and
transvaginal ultrasonography, three-dimensional
ultrasound, color Doppler ultrasonography and
tumor markers.12,13 However, none of these
methods used individually has shown
significantly better performance in detecting
malignant tumors from clinically restricted
ovarian masses. The development of a
mathematical formula using a logistic model,
incorporating menopausal status, the serum level
of a glycoprotein called CA 125 (which is
considered to be a tumor marker) and ultrasound
findings in a score system, has been described in
the literature in the form of different malignancy
indexes. These indexes were calculated using a
simplified regression equation obtained from the
product of the ultrasound findings score, the
menopausal status score and the absolute value
of CA 125 serum levels. Jacobs et al. originally
developed the risk-of-malignancy index in 1990
and it is termed the risk-of-malignancy index
#1. Tingulstad et al. developed a risk-of-
malignancy index in 1996, known as risk-of-
malignancy index #2 and in 1999 they modified
it to form the risk-of-malignancy index #3. The
difference between the three indices lies in the
different scorings of ultrasound findings and
menopausal status.14-16 All indices presented a
significantly better performance in diagnosing
malignancy than did each predictor taken
separately. These indices were tested by Morgante
et al.18 on another population with evident
malignant criteria in the ultrasonography, such
as hepatic or distant metastasis, and they found
that the risk-of-malignancy index #2 performed
better for detecting ovarian malignancy.
Previous studies did not show the use-
fulness of the score among women with lesions
clinically restricted to the ovaries and without
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clear evidence of malignancy. The purpose of
this study was to evaluate the risk-of-malig-
nancy index combining serum CA 125 levels,
ultrasound score and menopausal status, in
the preoperative diagnosis for women with
pelvic masses clinically restricted to the ovaries
and without clear evidence of malignancy.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
METHOD
Women with a pelvic mass apparently
restricted to the adnexal region who had
appointments for laparotomy at the Centro de
Atenção Integral à Saúde da Mulher, Univer-
sidade Estadual de Campinas were selected.
Between January 1996 and March 1998, 158
women were included in the study after signing
a consent form approved by the Research Ethics
Committee of the University. Twenty-one
patients with evident signs of hepatic and
intraperitoneal metastasis and six with lung
metastasis were excluded. The CA 125 serum
levels, ultrasound findings and menopausal
status were registered preoperatively.
Serum CA 125 samples were assayed by
radioimmunoassay (Malvern, Pennsylvania,
USA). The ultrasound examination was
performed using a 3.75-MHz abdominal convex
transducer (TOSHIBA SSA-140, Japan, and
ACUSON XP4A, USA). Women with tumors
bigger than 10 cm underwent transvaginal
scanning with a 7.5-MHz transducer. The lesions
were evaluated according to the shape, size,
multiplicity and presence of wall expansion
involvement or ascites. Morphological evaluation
was performed using the inner wall structure, wall
thickness, presence of septa and their thickness
and echogenicity.18,19 Six levels of increasing
malignancy and two levels of associated lesions
were defined. Using logistic regression, a score was
attributed to each ultrasound finding, termed the
ultrasound score. Postmenopausal status was
defined as more than one year of amenorrhea or
an age of more than 50 years in women who had
had a hysterectomy. All other women were
considered premenopausal. Women were
submitted to laparotomy, and the tissue excised
was sent for histopathological analysis.
Histopathological diagnosis was considered as the
gold standard for defining the outcome and it
was classified as benign or malignant.20
The diagnostic ability of each variable was
evaluated in a univariate analysis, using the
odds ratio as an associated measure. Most
relevant variables were included in a logistic
multiple regression model, fitted using the
ultrasound findings defined above, and the
serum CA 125 level and menopausal status.
This risk-of-malignancy index was calculated
with the attribution of values of 1 for preme-
nopausal status and 3 for postmenopausal
status (M), versus ultrasound score (US) and
the absolute values of CA 125 serum levels:
US x M x CA 125 (Table 1).
Sensitivity, specificity and likelihood ratio
were calculated for different cut-off points of
CA 125, ultrasound score and the resultant
risk-of-malignancy index. Empirical receiver
operating characteristic curves were used for
showing the overall diagnostic ability of serum
CA 125, ultrasound score and the risk-of-
malignancy index. All statistical analyses was
done using the SAS software, version 8.0.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
RESULTS
According to the histological examination
of the surgical specimens of the 158 women, 67
(42.4%) had malignant and 91 (57.6%) had
benign disease. The majority of the women with
malignant disease had ovarian cancer; one had a
Kruckenberg gall bladder tumor and three had
non-ovarian gynecological neoplasia. The
ovarian cancers included 37 at FIGO11 stage I,
two at stage II and 19 at stage IIIc of the disease.
Among women with stage III disease, 15 (79%)
presented only lymph node invasion (Table 2).
The sensitivity, specificity and positive and
Table 1. Risk-of-malignancy index according to ultrasound findings,
absolute values of CA 125 serum levels and menopausal status
Ultrasound findings Score
Unilocular simple cysts with regular fine wall or lesion suggesting dermoid cyst. 0
Multilocular cyst with regular and smooth wall (<3 mm) or thick (>3 mm) or solid
homogeneous tumor with hyperechogenic and well-defined wall. 1
Unilocular cyst or multilocular cyst with fine wall, with irregularity in the wall or septa (>3 mm). 2
Multilocular cyst with thick and irregular wall (irregularity <3 mm),
and/or irregular septa; or cyst with papillary irregularity over 3 mm. 4
Complex lesion, with predominance of cystic or solid area, without irregularity in surface. 5
Complex lesion with irregularity in surface (<3 mm) or badly-defined and
irregular wall; or solid heterogeneous lesion. 10
Multiplicity - Unilateral lesion or bilateral lesions. 0
Associated lesions: ascites 1
wall expansive involvement 2
greater than 3 mm
Ca 125 serum levels 0 - ∞
Premenopausal 1
Postmenopausal 3
Table 2. Distribution of diagnoses and the International Federation
of Gynecology and Obstetrics Stages
HISTOLOGICAL FINDINGS N
Ovarian carcinoma
Stage I borderline tumors 18
Stage I invasive tumors 19
Stage II 2
Stage IIIa 1
Stage IIIc (peritoneal masses) 4
Stage IIIc (lymph node) 15





Total malignant cases 67
Ovarian serous epithelial cysts 18
Ovarian mucinous epithelial cysts 12
Follicular cysts 7




Pelvic inflammatory disease 3
Endometriosis 4
Genital tuberculosis 1
Total benign cases 91
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negative likelihood ratios of serum CA 125,
ultrasound score and menopausal status are
reported in Table 3. The performance obtained
for a serum CA 125 level of 35 U/ml was a
sensitivity of 78% and specificity of 75%.
The sensitivity and the specificity of
ultrasound scores of three or four were 75%
and 71%, respectively. In the receiver ope-
rating characteristic curve evaluation, just as
in the logistic regression analysis, CA 125,
ultrasound score and menopausal status were
found to be relevant predictors of malignancy.
The area under the receiver operating
characteristic curve for CA 125 was 0.83 and
for the ultrasound score was 0.79 (Figure 1).
Sensitivity, specificity and likelihood ratios of
the risk-of-malignancy index at different cut-
off points are also showed in Table 3. The
confidence interval for the risk-of-malignancy
index was not estimated, because the receiver
operating characteristic curve variability
associated with this index could only be
evaluated using a second validation sample.
The performance obtained for the risk-of-
malignancy index at the cut-off point of 150
was a sensitivity and specificity of 79%. The
area under the receiver operating characteristic
curve for the risk-of-malignancy index was
0.90, which was more than the area for the
CA 125 serum levels (Figure 2).
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
DISCUSSION
In women without evidence of advanced-
stage ovarian cancer, the current risk-of-
malignancy index is useful in clinical practice
for differentiating malignant from benign
pelvic masses, as compared to each individual
component measured separately. In the present
population, this index was more accurate in
comparison with the best individual predictor
and CA 125 serum level. No increase in the
accuracy was observed when analyzing
patients' ages, tumor measurements or
bilaterally. The validity of the index depends
on the proportions of malignant neoplasm and
benign processes and the proportions of initial
and advanced stages.21,22
In both studies carried out by Jacobs et
al.14 and Tingulstad et al.,15,16 a non-selected
population was used that included patients
with systemic metastases. At a cut-off point
of 200, Jacobs et al. found a sensitivity of 73%
and a specificity of 91%. Tingulstad et al.
found a sensitivity of 76% and specificity of
82% in 1996, and 74% and 91% respectively
in 1999. The index showed itself useful in
referring patients with advanced neoplasia toFigure 2. Receiver operating characteristic curves for the risk-of-malignancy index (RMI) and CA 125 levels in the
discrimination between benign and malignant pelvic masses.
Figure 1. Receiver operating characteristic curves of the individual predictors showing the relationship between sensitivity and
specificity of CA 125 serum level, ultrasound score (US) and  menopausal status (M) in the discrimination between benign and
malignant pelvic masses.
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Table 3. Sensitivity, specificity and likelihood ratios for predicting malignancy of CA 125
serum levels, ultrasound score, menopausal status and the risk-of-malignancy index
Variables Sensitivity 95% CI Specificity 95% CI Likelihood Likelihood
(%) (%) Ratio (+) Ratio (-)
CA 125 (u/ml) *
10 94 ( 84 - 98 ) 26 ( 17 - 37 ) 1.27 0.23
35 78 ( 65 - 86 ) 75 ( 64 - 83 ) 3.12 0.29
50 61 ( 48 - 73 ) 88 ( 78 - 94 ) 5.08 0.44
65 52 ( 39 - 64 ) 91 ( 82 - 96 ) 5.77 0.53
150 27 ( 17 - 39 ) 97 ( 89 - 99 ) 9.00 0.75
Ultrasound
Score *
1 98 ( 90 - 99 ) 24 ( 16 - 35 ) 1.29 0.08
2 82 ( 70 - 90 ) 67 ( 56 - 76 ) 2.48 0.27
3 75 ( 62 - 84 ) 71 ( 60 - 80 ) 2.59 0.35
4 75 ( 62 - 84 ) 73 ( 62 - 81 ) 2.78 0.34
8 43 ( 31 - 56 ) 89 ( 80 - 94 ) 3.91 0.64
Postmenopausal
Status 73 ( 60 - 83 ) 69 ( 58 - 78 ) 2.35 0.39
Risk of
malignancy index *
30 96 56 2.18 0.07
100 84 77 3.65 0.21
150 79 79 3.76 0.27
200 73 86 5.21 0.31
500 63 97 21.00 0.38
*Cut-off point; CI: Confidence Interval.
a more complex healthcare unit. They reported
that 22% of the cases were in stage I and 35%
in II. Although the previous indices were
applied to cases in more advanced stages, quite
possibly the best application for the index
could be for those cases without
ultrasonographic evidence of malignancy. This
occurs because the risk-of-malignancy index
system translates the morphological
description of pelvic mass into objective
numerical data, reducing the bias attributable
to the examiner's subjectivity. The recent
development of ultrasound techniques and the
better characterization of malignant masses by
this method have led to better performance
by ultrasound as a predictor of malignancy,
especially in those cases with hepatic,
intraabdominal or neighboring organ me-
tastases.13 Ascites associated with pelvic masses
is a recognized sign of malignancy.23 Some
cases of rare non-neoplastic conditions are also
associated with ascites. Despite this, no
association was found between ascites and
malignancy in this study, in a univariate
analysis (data not shown).
In the present study, the malignant ovarian
neoplasm group consisted mainly of early
invasive or borderline tumors (67%). Among
the advanced tumors, the majority of the stage
III cases were so classified due to lymph node
invasion. None of the cases presented clear
preoperative evidence of metastasis. Borderline
tumors and benign processes can be treated in
a general hospital by gynecologists, although
invasive neoplasia, particularly advanced
invasive cases, merits appropriate therapy by
highly skilled surgical teams in specific oncology
centers. The risk-of-malignancy index facilitates
the selection of cases for referral to an
oncological unit and also helps the surgeon to
choose the surgical approach. For example: a
premenopausal 35-year-old woman with a solid
well-defined wall tumor and a CA 125 serum
level of 45 U/ml presents a risk-of-malignancy
index of 45. At the cut-off point of 150, the
tumor can be considered as benign and the
false-negative probability is around 21%.
However, the probability at the cut-off point
of 100 is 16%. A tumor with the same cha-
racteristics, in a postmenopausal 65-year-old
woman, with a CA 125 level of 97 U/ml has
a risk-of-malignancy index of 291. At the cut-
off point of 150, this tumor can be considered
as malignant with a false-positive probability
of around 21%, and at the cut-off point of 200
this tumor is still considered as malignant, with
a false-positive probability of 14%.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
CONCLUSION
In conclusion, the risk-of- malignancy
index is apparently able to identify the
probability of malignant pelvic masses, by
incorporating serum CA 125 serum levels,
ultrasound morphology and menopausal
status, performed individually in women with
ovarian masses. The main purpose of this study
was the evaluation of a risk-of-malignancy
index defined in a selected population of
apparently early lesions. This index is a simple
score system which can be applied directly to
clinical practice and might be of value in the
preoperative assessment of the adnexal mass.
It showed itself useful in referring patients with
advanced neoplasia to a more complex
healthcare unit, although it does not seem to
show prognostic value. However, the
performance of the present index must be
evaluated in other studies, using a validation
sample from a similar population.
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CONTEXTO: Não existem métodos pré-opera-
tórios adequados para diferenciar massas
pélvicas benignas de malignas. A avaliação do
CA 125, dos achados ultra-sonográficos e do
estado menstrual têm sido testados como
métodos diagnósticos isolados. O uso destes
três métodos em associação poderia levar a
um aumento do seu desempenho.
OBJETIVOS: Avaliar o índice de risco de malig-
nidade incorporando a dosagem de CA 125
sérico, escore ultra-sonográfico e estado
menopausal, no diagnóstico pré-operatório de
mulheres com massas pélvicas clinicamente
restritas ao ovário e sem evidências claras de
malignidade.
TIPO DE ESTUDO: Estudo de corte transversal.
LOCAL: Centro de Atenção Integral à Saúde da
Mulher, Universidade Estadual de Campinas.
PARTICIPANTES: 158 mulheres admitidas en-
tre janeiro de 1996 à março de 1998 para ex-
ploração cirúrgica de massa pélvica ovariana.
PROCEDIMENTOS: O índice de risco de ma-
lignidade foi calculado como US x M x CA
125, avaliados pré-operatoriamente. Achados
ultra-sonográficos foram classificados de acor-
do com a forma, tamanho, multiplicidade,
presença de envolvimento de parede ou ascite
em um sistema de escore (US). Para o estado
menopausal foi considerada a pontuação de
1 para pré-menopausal e 3 para pós-meno-
pausal (M), e a dosagem dos níveis séricos de
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
RESUMO
CA 125 sérico foi considerada em seu valor
absoluto.
ANÁLISE ESTATÍSTICA: As variáveis mais re-
levantes foram incluídas em um modelo de
regressão logística múltipla, usando o escore
ultra-sonográfico, o nível de CA 125 e o es-
tado menopausal. Foi usada para avaliar o
desempenho de cada preditor individual em
determinar a malignidade destes tumores e
identificar o índice de risco de malignidade.
RESULTADOS: O melhor desempenho individual
foi encontrado na dosagem de CA 125 (sensi-
bilidade de 78%, especificidade de 75%), se-
guido pelo escore ultra-sonográfico (sensibili-
dade de 75%, especificidade de 73%) e esta-
do menopausal (sensibilidade de 73%,
especificidade de 69%). O desempenho obti-
do pelo índice de risco de malignidade no pon-
to de corte de 150 foi sensibilidade e
especificidade de 79%. A área sob a curva ROC
para o índice de risco de malignidade foi 0,90,
maior que a área para o CA 125 (0,83) ou
escore ultra-sonográfico (0,79).
CONCLUSÃO: O índice de risco de malignida-
de usando escore morfológico ultra-
sonográfico, dosagem de CA 125 sérico e es-
tado menopausal pode ser de valor no acesso
pré-operatório do carcinoma ovariano.
PALAVRAS-CHAVE: Câncer de ovário. CA 125.
Ultra-sonografia. Estado menopausal. Risco
de malignidade.
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